Postpartum Depression Drug Market 2018 With Major Key Players Sage Therapeutics, Sun Pharmaceutical Industries, Cipla Limited, Intas Pharmaceuticals, Mylan

Postpartum depression (PPD), also known as postnatal depression, is a type of mood disorder that results post pregnancy. Signs of depression include, insomnia, fatigue and sadness, loss of appetite, mood swings, anxiety, and anger. Hormonal changes such as elevated prolactin levels, depleted oxytocin and thyroid hormone levels can be a cause of PPD in females.

Postpartum Depression Drug Market– Drivers

Increasing research activities for treatment of PPD is expected to propel growth of the postpartum depression drug market during the forecast period. For instance, Sage Therapeutics is undergoing phase 3 clinical study for the drug —Brexanolone, which might be useful in the treatment of PPD. The study started in May 2018 and is estimated to be completed in September 2020.

Furthermore, Marinus Pharmaceuticals, is undergoing clinical phase 2 study for the drug Ganaxolone in the treatment of PPD and other mood associated disorders. The clinical study started in June 2017 and is expected to be completed in June 2019.

Get Discount On This Report:
https://www.coherentmarketinsights.com/insight/request-discount/2258

Postpartum Depression Drug Market– Taxonomy

By Drug Class

Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
Tricyclic Antidepressants
Atypical Antidepressants
Monoamine Oxidase Inhibitors (MAOIs)
Others
By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Postpartum Depression Drug Market– Restraint

Antidepressant drugs refusals by the U.S. Food and Drug Administration (U.S FDA) are expected to be a major restraint in growth of the postpartum depression drug market over the forecast period. For instance, in April 2018, the U.S FDA refused New Drug Application of Alkermes plc.’s drug candidate ALKS 5461 which is to be administered orally. The drug could be useful in treating depressive disorders, which cannot be treated by other standard drug therapies. This refusal was due to failures in action of this oral medication.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/2258

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.